Table 2.
Significant factors associated with polyautoimmunity.
| SLE | RA | MS | SSc | |||||
|---|---|---|---|---|---|---|---|---|
| AOR; CI95% | P | AOR; CI95% | P | AOR; CI95% | P | AOR; CI95% | P | |
| Female gender | 2.3; 1.03–5.15 | 0.043 | 1.8; 1.22–6.31 | 0.015 | 8.5; 1.02–70.8 | 0.048 | 9.08; 2.09–39.3 | 0.003 |
| Familial autoimmunity | 1.61; 1.14–2.28 | 0.007 | NS | NS | 2.62; 1.24–5.54 | 0.01 | ||
| Articular Involvement | 2.02; 1.26–3.23 | 0.003 | NS | NE | NS | |||
| Anti-Ro positivity | 1.54; 1.10–2.16 | 0.013 | NS | NE | NS | |||
| Cardiovascular disease | NS | 2.2; 1.17–3.94 | 0.014 | NE | NE | |||
| ANAs | NS | 2.0; 1.08–3.84 | 0.027 | NS | ||||
| SSEP | NE | NE | 10.86; 1.31–89.6 | 0.027 | NE | |||
SLE: systemic lupus erythematosus; RA: rheumatoid arthritis; MS: multiple sclerosis; SSc: systemic sclerosis; AOR: adjusted odd ratio; CI95%: confidence interval; ANAs: antinuclear antibodies; SSEP: somatosensory evoked potentials; NS: nonsignificant; NE: not evaluated.